Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)
Project Number5P01AA029540-02
Contact PI/Project LeaderCROPSEY, KAREN L Other PIs
Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
Project Summary/Abstract
The overall aims of the Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA) are to (Aim 1) test
the effectiveness of a transdiagnostic model, Common Elements Treatment Approach (CETA), to reduce
unhealthy alcohol use and improve HIV clinical outcomes in under-resourced HIV clinics, (Aim 2) evaluate the
mechanisms through which CETA impacts HIV outcomes, (Aim 3) investigate whether the treatment effect of
CETA varies by clinical (e.g., presence of comorbidities), demographic (e.g., gender) and/or contextual factors
(e.g., Zambia, Alabama), and (Aim 4) examine implementation factors, including cost, related to integrated
delivery of alcohol reduction interventions to disadvantaged people with HIV and unhealthy alcohol use at front-
line HIV clinics. The P01’s central theme is that, among people with HIV and unhealthy alcohol use, integrated
screening and treatment of common behavioral and mental health comorbidities will lower unhealthy alcohol use
and improve HIV treatment outcomes. ZAMBAMA will be implemented by a collaborative team that brings
together groups of established and young investigators working to address scientific gaps at the nexus of HIV,
substance use, and mental illness in priority geographical areas in the global HIV response: sub-Saharan Africa
and the Southern U.S. Together, the team will implement two randomized controlled clinical trials in adults with
HIV and unhealthy alcohol use to evaluate CETA’s effects on alcohol use, the HIV care continuum (antiretroviral
therapy adherence, engagement and retention in HIV care, viral suppression), and common mental health and
substance use comorbidities. Project 1 (CETA HIV Alcohol Reduction Trial in Zambia - CHARTZ) will be
implemented at public sector primary HIV clinics in Zambia where existing HIV ‘peer educators’ (i.e., lay
counselors) will be trained to provide an alcohol brief intervention (BI) and CETA to participants at in-person
sessions. Project 2 (Telemedicine for Unhealthy Alcohol Use in Persons Living with HIV using CETA - TALC)
will enroll participants receiving HIV care at community Ryan White HIV/AIDS program-funded clinics across
Alabama that serve diverse and rural populations. Graduate-level providers (supervised by a licensed clinical
psychologist) will provide the interventions (BI and CETA) remotely using telemedicine approaches that were
rapidly expanded during the COVID-19 pandemic. Both research projects will also evaluate implementation
factors, to enhance the impact of clinical effectiveness data, and both projects will be supported by 3 resource
cores: a CETA core for clinical intervention training and oversight, a Methods and Analysis core to harmonize
data elements across projects and create synergy in data analyses, and an Administrative core to manage
business and regulatory requirements of the P01, monitor and manage overall progress, and promote
bidirectional knowledge and idea exchange between Southern U.S.- and sub-Saharan Africa-focused
investigators.
Public Health Relevance Statement
Project Narrative
Unhealthy alcohol use represents an unaddressed barrier to achieving and maintaining control of the HIV
epidemic globally. In the Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA), we will compare
the effectiveness of an alcohol brief intervention and a transdiagnostic cognitive behavioral therapy-based model
that can address unhealthy alcohol use and a range of comorbid mental health problems to improve HIV and
alcohol outcomes among low-resource and underserved patients with HIV and unhealthy alcohol use in sub-
Saharan Africa and the Southern United States. ZAMBAMA’s 2 research projects and 3 resource cores were
designed for integration and synergy, which will not only strengthen our ability to address our specific aims, but
will also create unique scientific opportunities that would not be possible without a program structure.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS/HIV problemAcquired Immunodeficiency SyndromeAddressAdherenceAdultAfrica South of the SaharaAlabamaAlcohol consumptionAlcoholsAnxietyApacheArizonaBackBusinessesCOVID-19 pandemicCaringClinicClinicalClinical effectivenessCognitive TherapyCollaborationsCommunitiesComplexContinuity of Patient CareDataData AnalysesData CollectionData ElementDeep SouthDisadvantagedEducational InterventionElementsEnrollmentEpidemicEvidence based interventionFaceFundingGenderGeographic LocationsHIVHealth PersonnelHuman ResourcesIncidenceInfectious Diseases ResearchInterpersonal ViolenceInterventionKnowledgeMental DepressionMental HealthMental disordersMethodsModelingMonitorNational Institute on Alcohol Abuse and AlcoholismOutcomePainParticipantPatientsPersonsPopulation HeterogeneityPrevalencePreventionProfessional counselorProtocols documentationProviderPsychologistPublic SectorRandomized Controlled Clinical TrialsRandomized Controlled TrialsResearchResearch PersonnelResearch Project GrantsResourcesRural PopulationSouthern AfricaStructureSupervisionTelemedicineTrainingTranslatingTreatment outcomeUnderserved PopulationUnited StatesUnited States National Institutes of HealthViralZambiaaddictionalcohol comorbidityalcohol misuseantiretroviral therapybasebehavioral healthbehavioral health interventionbrief alcohol interventionbrief interventioncommon treatmentcommunity cliniccomorbiditycompare effectivenesscontextual factorscostcost effectivedata harmonizationdesigneffectiveness testingimplementation determinantsimplementation evaluationimprovedlow and middle-income countriesmortalitypeerpilot testpopulation basedpost-traumatic stresspost-traumatic symptomsprogramsreduce symptomsresponsescreeningsubstance usesuicidal risksynergismtherapy adherencetreatment as preventiontreatment effecttrial design
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
10-September-2021
Project End Date
31-August-2026
Budget Start Date
01-September-2022
Budget End Date
31-August-2023
Project Funding Information for 2022
Total Funding
$1,137,273
Direct Costs
$979,527
Indirect Costs
$157,746
Year
Funding IC
FY Total Cost by IC
2022
National Institute on Alcohol Abuse and Alcoholism
$1,137,273
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AA029540-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AA029540-02
Patents
No Patents information available for 5P01AA029540-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AA029540-02
Clinical Studies
No Clinical Studies information available for 5P01AA029540-02
News and More
Related News Releases
No news release information available for 5P01AA029540-02
History
No Historical information available for 5P01AA029540-02
Similar Projects
No Similar Projects information available for 5P01AA029540-02